Oxford Cannabinoid Technologies appoint new CEO and renews licence
Oxford Cannabinoid Technologies Holdings PLC has appointed Clarissa Sowemimo-Coker as chief executive.
Sowemimo-Coker, who has been with Oxford Cannabinoid Technologies for four years, was working as interim CEO prior to her official appointment.
As head of the company Sowemimo-Coker has already led Oxford Cannabinoid Technologies to its first submission to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Wales Research Ethics Committee 2 (REC 2).
The chair of Oxford Cannabinoid Technologies Julie Pomeroy said: "It is my pleasure, on behalf of the OCTP board, to congratulate Clarissa on her appointment as permanent CEO of the company.
"Since taking on the role on an interim basis, Clarissa has demonstrated her dedication and ability to lead the company as we continue to make significant progress towards our goals."
The company has also announced the renewal of its subsidiary, Oxford Cannabinoid Technologies LTD, has had its home office licence renewed for the fifth year running – allowing the company to possess and supply schedule one drugs for research purposes.
Oxford Cannabinoid Technologies is also making progress towards commencing a phase I clinical trial for its lead drug candidate, OCT461201. The trials will be able to proceed once the UK medicines regulatory authorities provide approval.
Read more – New Kent lab complex attracts multiple tenants
